Investors Chronicle

Subscribe today and save 57%

Investors Chronicle print and digital editions

Mark Robinson

ConvaTec's $150m tranformation

The medical products group has been hit by another markdown following October's profit warning

ConvaTec's $150m tranformation

Clinigen acquires US rights to major cancer drug

Clinigen acquires US rights to major cancer drug

HMV vs Focusrite – the case for specialism

The contrasting fortunes of HMV and Focusrite could point to a wider divergence in the consumer market

Mark Robinson

Apollo given extension on RPC bid

Apollo given extension on RPC bid

Earthport into orbit on Visa bid

Earthport into orbit on Visa bid

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office